Abstract 201P
Background
Immunotherapy provided a new treatment alternative for cancer, but many patients still do not respond due to tumor-induced immunological dysfunction. Aerobic exercise training (AET) has emerged as a strategy to reduce cancer mortality and improve immune response, however the mechanisms explaining AET benefits immune system on cancer remain unclear. Thus, our aim was to evaluate whether AET could positively modify the tumor microenvironment, favoring infiltration and cytotoxicity of “antitumor” lymphocytes by regulating their mitochondrial content and function.
Methods
Balb/c male mice were submitted to 4 weeks of AET (60% of maximal capacity, 5 days/week, 1 h/day) before inoculation (s.c.,1x106 CT26 colon carcinoma cells). CT26 TR continued AET after inoculation and all groups were euthanized 9 days post tumor cells inoculation for further analysis. Tumor volume was measured daily. Experimental groups were divided into control (healthy sedentary mice), CT26 SED (sedentary tumor-bearing mice) and CT26 TR (trained tumor-bearing mice). Tumor-infiltrated T lymphocytes and mitochondrial density were measured by flow cytometry. Tumor hypoxia was measured by Hypoxyprobe Kit. Mitochondrial morphology was evaluated by electron microscopy and ATP production by an ATP Determination Kit. Statistical analysis: Anova One-way, Duncan post hoc, p<0.05. Ethical approval: CEUA EEFE-USP 2017/02.
Results
CT26 TR mice showed attenuated tumor progression when compared with CT26 SED group, with significant smaller tumor volume and mass. AET significantly reduced tumor hypoxic area compared to CT26 SED group. AET significantly increased the total amount of activated and effector memory CD8+ T cells, and effector memory CD4+ T cells in CT26 TR when compared to CT26 SED in the tumor. Additionally, increased function of T CD8+ cells in CT26 TR was followed by a higher mitochondrial number/cell and function (ATP production) in this cells compared with CT26 SED group.
Conclusions
AET increases tumor-infiltrated cytotoxic/effector CD8+ T cells and improves their mitochondrial content and function. These data suggest that AET can attenuate tumor growth by modulation of tumor-infiltrated lymphocytes number and profile.
Legal entity responsible for the study
The authors.
Funding
São Paulo Research Foundation (FAPESP, 11800-4/2021, 2015/22814-5, and 2017/13133-0).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
126P - Evaluation of Myeloid Targeting Agents, PY159 and PY314, in Two Dose Expansion Phase 1b Trials in Platinum-Resistant Ovarian Cancer
Presenter: Oladapo Yeku
Session: Poster Display
116TiP - Randomized, open-label, phase II study of botensilimab (BOT) alone and in combination with balstilimab (BAL) versus standard-of-care in patients with refractory metastatic colorectal cancer
Presenter: Eric Van Cutsem
Session: Poster Display
127P - REGN5668 (MUC16xCD28 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase 1 dose-escalation study
Presenter: Ira Winer
Session: Poster Display
128P - A phase I dose escalation and expansion trial of LYT-200, a Galectin-9 antibody +/- tislelizumab
Presenter: Gerald Falchook
Session: Poster Display
129P - Naxitamab efficacy in patients with refractory/relapsed high-risk neuroblastoma and bone metastases as assessed by Curie score
Presenter: Brian Kushner
Session: Poster Display
131P - Safety and clinical efficacy of Roginolisib (IOA-244), the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3K_)
Presenter: Anna Di Giacomo
Session: Poster Display
132P - A phase I clinical trial of QLS31905 in advanced solid tumors
Presenter: Yakun Wang
Session: Poster Display
133P - Phase 1/2 study of XTX101, a masked, tumor-activated Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors
Presenter: Diwakar Davar
Session: Poster Display
134P - A Phase 1 Study Exploring the Safety and Tolerability of the Small Molecule PD-L1 Inhibitor INCB099318 in Select Advanced Solid Tumors
Presenter: David Pinato
Session: Poster Display
135P - Isunakinra as Monotherapy and Combined with Nivolumab for Treatment Resistant Advanced Solid Tumours: Exploratory Effect Data, Tolerability, and Pharmacokinetics from a Dose Escalation Trial
Presenter: Carlos Becerra
Session: Poster Display